Yüklüyor......
Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults
Eculizumab, a humanized anti–complement C5 monoclonal antibody (mAb) for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome, blocks the terminal complement pathway required for serum bactericidal activity (SBA). Because treated patients are at >1000-fold...
Kaydedildi:
| Yayımlandı: | Blood |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5561903/ https://ncbi.nlm.nih.gov/pubmed/28630122 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-781450 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|